文献速递免疫规划卫生政策与健康促进

哥伦比亚儿童将通用接种从PCV10转换为PCV13的成本效果分析

How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
PubMed 文献 · Vaccine · 2018-08-04

该经济分析评估哥伦比亚儿童从PCV10转换为PCV13相比继续PCV10的流行病学与经济影响。转换可避免587例门诊CAP、1622例住院CAP、10例肺炎球菌脑膜炎和79例死亡;每挽救生命年ICER为1771美元(95%CI 1285-9884),低于人均GDP 6631美元的支付意愿阈值。作者认为转换是划算的,但决策还需考虑其他标准。

要点

  • 转换为PCV13可避免587例门诊CAP、1622例住院CAP、10例脑膜炎和79例死亡。
  • 转换的每挽救生命年ICER为1771美元(95%CI 1285-9884),低于支付意愿阈值6631美元。
  • 继续PCV10为扩展劣势方案,转换PCV13更受偏好,敏感性分析结果稳健。

核心结论

  • 在哥伦比亚儿童中,从PCV10转换为PCV13相比继续PCV10具有成本效果,可预防额外肺炎球菌疾病负担并节省治疗费用,但决策还需考虑其他标准。

研究设计与样本

  • 完整经济学分析,评估从PCV10转换为PCV13相比继续PCV10的流行病学与经济影响。
  • 流行病学信息来自哥伦比亚国家卫生研究所基于实验室的肺炎球菌分离株监测,经济投入来自文献,增量效果基于PCV13额外覆盖的血清型。
  • 采用增量成本效果比(ICER)评估,支付意愿阈值为人均GDP 6631美元/挽救生命年(YLS),成本以2014年美元报告,并进行确定性和概率敏感性分析,报告95%置信区间。

主要发现

  • 使用PCV10通用接种4年后,哥伦比亚卫生监测系统显示非PCV10分离株相对增加。
  • 从PCV10转换为PCV13可避免587例门诊处方社区获得性肺炎(CAP)(95%CI -49-1008)、1622例住院处方CAP(95%CI 591-2343)、10例肺炎球菌脑膜炎(95%CI 6-11)和79例死亡(95%CI 76-98)。
  • 继续PCV10的每YLS ICER为2319美元(95%CI 被支配-4225美元),转换为PCV13的每YLS ICER为1771美元(95%CI 1285-9884美元)。
  • 尽管继续PCV10具有成本效果,但其为扩展劣势方案,转换至PCV13更受偏好;敏感性分析中结果对参数变化稳健。

关键数值与推荐

  • 支付意愿阈值为人均GDP 6631美元/挽救生命年(YLS)。
  • 转换为PCV13相比继续PCV10可避免587例门诊CAP(95%CI -49-1008)、1622例住院CAP(95%CI 591-2343)、10例肺炎球菌脑膜炎(95%CI 6-11)和79例死亡(95%CI 76-98)。
  • 继续PCV10的每YLS ICER为2319美元(95%CI 被支配-4225美元),转换为PCV13的每YLS ICER为1771美元(95%CI 1285-9884美元)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children immunization with pneumococcal conjugate vaccine (PCV) had profound public health effects across the globe. Colombian adopted PCV10 universal vaccination, but PCV incremental impact need to be revalued. The objective of this analysis was to estimate the cost-effectiveness of switch to PCV13 versus continue PCV10 in Colombian children. METHODS: A complete economic analysis was carried-out assessing potential epidemiological and economic impact of switching from PCV10 to PCV13. Epidemiological information on PCV10 impact was obtained from lab-based epidemiological surveillance on pneumococcal isolates at the Colombian National Institute of Health. Economic inputs were extracted from the literature. Incremental PCV13 effectiveness was based in additional serotypes included. Comparisons among alternatives were evaluated with the Incremental Cost-Effectiveness Ratio (ICER) at a willingness to pay of one GDP per capita (USD$ 6631) per Year of Live Saved (YLS). All costs were reported in 2014USD. Deterministic and probabilistic sensitivity analyses were performed, and 95% confidence interval reported. RESULTS: After four years using PCV10 for universal vaccination on children the Colombian health surveillance system showed a relative increment on non PCV10 isolates. To change from PCV10 to PCV13 would avoid 587 (CI95% -49-1008) ambulatory Rx community-acquired pneumoniae (CAP), 1622 (CI95% 591-2343) Inpatient RxCAP, 10 (CI 95% 6-11) pneumococcal meningitis, and 79 (CI95% 76-98) deaths. ICER per YLS was USD$ 2319 (CI95% Dominated - USD$ 4225) for Keep-PCV10 and USD$ 1771 (CI95% USD$ 1285-9884) for Switch-to PCV13. In spite of its cost-effectiveness Keep-PCV10 is an extended dominated alternative and Switch-to PCV13 would be preferred. Results are robust to parameters changes in the sensitivity analyses. CONCLUSION: A national immunization strategy based in Switch-to PCV13 was found to be good value for money and prevent additional burden of pneumococcal disease saving additional treatment costs, when compared with to Keep-PCV10 in Colombia, however additional criteria to decision making must be taken into account.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Castañeda-Orjuela C, De la Hoz-Restrepo F. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine. 2018. PMID: 30087049. doi:10.1016/j.vaccine.2018.07.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。